viloxazine   Click here for help

GtoPdb Ligand ID: 11502

Synonyms: Emovit® | ICI-58,834 | ICI-58834 | Qelbree®
Approved drug
viloxazine is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Viloxazine was originally described as a selective norepinephrine reuptake inhibitor (NRI), principally based on its ability to potentiate noradrenergic effects. It also modulates 5-HT (serotonin) activity, via antagonistic activity at 5-HT2B and agonistic activity at 5-HT2C receptors, and it increases extracellular 5-HT levels in the prefrontal cortex (PFC) [4]. Viloxazine's chemical structure is different from conventional tri- or tetra-cyclic antidepressants. The INN stipulates a racemic mixture of enantiomers. We show the structure without specified stereochemistry to represent the mixture. The hydrocholride salt (SPN-812) was progressed by Supernus Pharmaceuticals for attention deficit hyperactivity disorder (ADHD) in children and adults.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 39.72
Molecular weight 237.14
XLogP 1.26
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOc1ccccc1OCC1CNCCO1
Isomeric SMILES CCOc1ccccc1OCC1CNCCO1
InChI InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3
No information available.
Summary of Clinical Use Click here for help
Viloxazine was used in some European countries as an antidepressant, but it was withdrawn from the market in the early 2000s. The FDA approved extended release viloxazine hydrochloride (Qelbree) as a treatment for ADHD in April 2021 [1]. This is indicated for 6-17 year old children.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03247530 Evaluation of SPN-812 ER Low Dose in Children With ADHD Phase 3 Interventional Supernus Pharmaceuticals, Inc. 2-3
NCT04016779 Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder Phase 3 Interventional Supernus Pharmaceuticals, Inc.